BioSpecifics Technologies Corp. (NASDAQ:BSTC) has earned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.

Analysts have set a twelve-month consensus price target of $81.00 for the company and are predicting that the company will post $0.68 earnings per share for the current quarter, according to Zacks. Zacks has also assigned BioSpecifics Technologies an industry rank of 84 out of 257 based on the ratings given to related companies.

BSTC has been the topic of a number of recent analyst reports. BidaskClub lowered BioSpecifics Technologies from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 4th. HC Wainwright set a $65.00 target price on BioSpecifics Technologies and gave the company a “buy” rating in a research report on Friday, August 10th. Finally, Zacks Investment Research upgraded BioSpecifics Technologies from a “hold” rating to a “strong-buy” rating and set a $62.00 target price on the stock in a research report on Tuesday, August 14th.

In related news, Director Paul Gitman sold 19,000 shares of the stock in a transaction on Wednesday, August 29th. The stock was sold at an average price of $49.72, for a total value of $944,680.00. Following the completion of the transaction, the director now directly owns 30,000 shares of the company’s stock, valued at approximately $1,491,600. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Of Edwin H. Wegman Estate sold 7,935 shares of the stock in a transaction on Saturday, September 1st. The shares were sold at an average price of $37.53, for a total value of $297,800.55. Following the completion of the transaction, the insider now directly owns 1,005,128 shares of the company’s stock, valued at $37,722,453.84. The disclosure for this sale can be found here. Insiders have sold a total of 70,247 shares of company stock worth $3,368,139 in the last quarter. Insiders own 21.40% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Morgan Stanley raised its stake in BioSpecifics Technologies by 18.1% in the 3rd quarter. Morgan Stanley now owns 28,887 shares of the biopharmaceutical company’s stock valued at $1,690,000 after purchasing an additional 4,423 shares during the last quarter. MetLife Investment Advisors LLC acquired a new position in BioSpecifics Technologies in the 3rd quarter valued at $273,000. Matarin Capital Management LLC acquired a new position in BioSpecifics Technologies in the 3rd quarter valued at $1,324,000. Allianz Asset Management GmbH raised its stake in BioSpecifics Technologies by 5.0% in the 3rd quarter. Allianz Asset Management GmbH now owns 69,865 shares of the biopharmaceutical company’s stock valued at $4,086,000 after purchasing an additional 3,353 shares during the last quarter. Finally, Bridgeway Capital Management Inc. raised its stake in BioSpecifics Technologies by 5.1% in the 3rd quarter. Bridgeway Capital Management Inc. now owns 43,530 shares of the biopharmaceutical company’s stock valued at $2,546,000 after purchasing an additional 2,130 shares during the last quarter. 57.95% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:BSTC traded down $0.25 during midday trading on Wednesday, reaching $55.97. 22,078 shares of the company’s stock traded hands, compared to its average volume of 29,166. BioSpecifics Technologies has a 1 year low of $38.05 and a 1 year high of $66.21. The firm has a market capitalization of $425.04 million, a price-to-earnings ratio of 32.92 and a beta of 1.48.

BioSpecifics Technologies (NASDAQ:BSTC) last announced its earnings results on Friday, November 9th. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.14. BioSpecifics Technologies had a return on equity of 20.81% and a net margin of 54.96%. The firm had revenue of $8.17 million for the quarter, compared to analyst estimates of $7.19 million. As a group, analysts forecast that BioSpecifics Technologies will post 2.5 earnings per share for the current year.

BioSpecifics Technologies Company Profile

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brand names.

See Also: What is Cost of Debt?

Get a free copy of the Zacks research report on BioSpecifics Technologies (BSTC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.